Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.
about
Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomicsTreatment of the elderly post-myocardial infarction patientUse of NHANES data to link chemical exposures to chronic diseases: a cautionary taleImplications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic targetOxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study.Cardiovascular risk determination: discrepancy between total cholesterol evaluation and two compound laboratory indices in NorwayCurrent concepts in secondary prevention after acute myocardial infarction.Evaluation of cardiovascular risk in blood donors: results of the CARDIORISK study in the Parma Transfusion Service.Is hypercholesterolemia a risk factor and should it be treated in the elderly?Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics.The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link.Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association.Lipid-lowering drug use and cardiovascular events after myocardial infarction.Multiple cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group.Comparison of predictive value of cardiometabolic indices for subclinical atherosclerosis in Chinese adults.Long-term prognostic importance of total cholesterol in elderly survivors of an acute myocardial infarction: the Cooperative Cardiovascular Pilot Project.Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study.Lipid-lowering therapy in older personsManaging hyperlipidaemia in the elderly: special considerations for a population at high risk.Cholesterol and cardiovascular disease in the elderly. Facts and gaps.Treatment after myocardial infarction.Effect of Persistence with Drug Therapy On the Risk of Myocardial Re-infarction.Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Management of older persons after myocardial infarction.Cholesterol in patients with coronary heart disease: how low should we go?A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?Coronary artery disease--more disease, more patients, better treatment.Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden.How to read critically a prognostic cohort study.Human genetics as a foundation for innovative drug development.Prevalence of coronary artery disease, atherothrombotic brain infarction, and peripheral arterial disease: associated risk factors in older Hispanics in an academic hospital-based geriatrics practice.Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study.Association of insulin resistance to electrocardiographic changes in non obese Asian Indian subjects with hypertension.Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
P2860
Q26853114-950FC836-A3D1-40BB-9D1F-3F14AF82560BQ28191018-A53BE3EA-6C01-45E5-A965-59A9A0660DA2Q28485472-DF46D17C-B62C-4EEA-BD60-733926CC2455Q30370672-07E42770-FEB6-4733-BB86-A0F41344A317Q33653555-50C58FDF-8090-4BE6-8005-65209AB7FB33Q33702516-CA33F207-8B1F-45F5-BA63-C45A2D3CD41BQ33860933-42012520-FC18-4BD4-A5E7-6F95C07FAE33Q34003468-46DCA9F0-6F58-4085-9DF3-33296DC49361Q34077942-33CA0AD2-A9F2-4E59-955B-DB0DCCF26636Q34107382-3D804CFB-3742-4629-B929-178B548EAD1FQ34146972-7D94E206-435B-48E7-BE34-77804437EA78Q34224601-BC61B055-5145-4802-AF68-EA410E8F29BFQ34615583-DDE7214B-8978-4280-A541-CA698444A120Q34725347-7E64DCB7-70A5-4B0C-BA44-0E7F8EDBFB4FQ35137575-9E56CD5D-8080-4646-B278-B0C6E1DA3ADCQ35166425-B650B4EF-37D0-49A6-BB3C-7BDEFD93E4D5Q35187308-86EF3964-76F9-4207-A200-68BF94D6DC19Q35232239-1417C785-3B39-4E1A-9000-7A2517469AA0Q36445474-91A2424D-A7DD-49A4-B0E9-DC2D89A4E8F5Q36863052-C7F31755-2411-4BD0-8F46-701AB3E477C9Q36993983-6F6FCF08-AD95-4E36-B8A5-B8397F1589D6Q37195899-A4841E83-83AA-4B90-9FE9-C6775B6950FFQ37706943-8E1153A8-FFF7-4C54-893A-9C49D5EAD3B8Q37855801-E8EC69FF-C846-48C0-9584-8C9847E4636EQ39443735-59527C3C-9A3B-494C-AFB9-91A4145735D3Q40368068-23BC8489-D27C-4AEC-A5A8-27F5FF6591E4Q42879876-94C32B7D-67C3-453A-ACC5-C94941119B00Q44125966-5DB00EF1-5BE4-4426-B158-C7A3C4691668Q44328105-ED137938-D804-4E7B-87DD-47B374D0B03CQ44416953-E746603E-E557-41BA-BDCE-104351008214Q45182500-BFEA7239-FD88-49F8-8565-FC42F1EC58ADQ46007453-37E0DD80-77A5-43D0-94EB-B1B27398398EQ48483930-9CD9BAF7-335C-4509-9C6C-A8FDF50F18BDQ50099169-217D7532-63DA-47BB-9086-74A6A703DF1CQ50866424-DA8983DF-0874-4CE0-8F67-0D967965A54AQ51926489-696BB80A-2F22-42EF-8BCD-0291A3C4F6CB
P2860
Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Serum cholesterol as a prognos ...... arction: the Framingham Study.
@en
Serum cholesterol as a prognos ...... arction: the Framingham Study.
@nl
type
label
Serum cholesterol as a prognos ...... arction: the Framingham Study.
@en
Serum cholesterol as a prognos ...... arction: the Framingham Study.
@nl
prefLabel
Serum cholesterol as a prognos ...... arction: the Framingham Study.
@en
Serum cholesterol as a prognos ...... arction: the Framingham Study.
@nl
P2093
P1476
Serum cholesterol as a prognos ...... arction: the Framingham Study.
@en
P2093
P304
P356
10.7326/0003-4819-115-9-687
P407
P577
1991-11-01T00:00:00Z